LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Public ClinicalTrials.gov record NCT05900986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Single-arm, Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer
Study identification
- NCT ID
- NCT05900986
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Integro Theranostics
- Industry
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Interventions
- LS301-IT 0.025 mg/kg Drug
- LS301-IT 0.05 mg/kg Drug
- LS301-IT 0.075 mg/kg Drug
- LS301-IT 0.1 mg/kg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2023
- Primary completion
- Oct 5, 2025
- Completion
- May 5, 2026
- Last update posted
- May 19, 2026
2023 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Integro Theranostics Research Site #2 | Scottsdale | Arizona | 85260 | — |
| Integro Theranostics Research Site #12 | Washington D.C. | District of Columbia | 20059 | — |
| Integro Theranostics Research Site #9 | Weston | Florida | 33331 | — |
| Integro Theranostics Research Site #6 | The Bronx | New York | 10461 | — |
| Integro Theranostics Clinical Research Site #8 | Winston-Salem | North Carolina | 27103 | — |
| Integro Theranostics Research Site #10 | Cleveland | Ohio | 44195 | — |
| Integro Theranostics Research Site #5 | Philadelphia | Pennsylvania | 19107 | — |
| Integro Theranostics Research Site #3 | Dallas | Texas | 75290 | — |
| Integro Theronostics Research Site #1 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05900986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05900986 live on ClinicalTrials.gov.